logo
  

FireEye Selling Products Biz And Name For $1.2 Billion Cash

Shares of FireEye, Inc. (FEYE) slipped over 4% in extended trading session Wednesday after the cybersecurity company announced that it is selling its products business, including the FireEye name, to a consortium led by private-equity firm Symphony Technology Group for $1.2 billion in cash.

FireEye said the deal will split its network, email, endpoint, and cloud security products from Mandiant's controls-agnostic software and services. The deal is expected to close by the end of fourth quarter 2021.

"We believe this separation will unlock our high-growth Mandiant Solutions business and allow both organizations to better serve customers," said FireEye Chief Executive Officer Kevin Mandia. "After closing, we will be able to concentrate exclusively on scaling our intelligence and frontline expertise through the Mandiant Advantage platform."

Simultaneously, FireEye announced that its board has approved a $500 million share-repurchase plan.

Last year, FireEye said that it had been hacked, which the company says is likely a state-sponsored attack. The hacking tools used to test the defenses of its clients were stolen in the attack.

FEYE closed Wednesday's trading at $22.53, up $0.20 or 0.90%, on the Nasdaq. The stock, however, slipped $0.98 or 4.35%, in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The 737 MAX 10, Boeing Co.'s largest 737 Max model, is taking its maiden flight today, reports said citing people familiar with the matter. The flight after months of testing and certification will be around 10 a.m. local time from the Seattle area. The schedule could change depending on weather or other factors. Meanwhile, the jetliner is expected to enter commercial service in 2023. Medical devices supplier Smiths Medical, affiliated to Smiths Group plc, is recalling certain Jelco Hypodermic Needle-Pro Fixed Needle insulin syringes with skewed graduation markings, the U.S. Food and Drug Administration said. The recall was initiated after the company became aware of specific models and lots of Jelco insulin syringes that may exhibit skewed odd number line graduation markings. Saliva-based COVID-19 testing is rolled out as a pilot for public schools in New York City. The new two-month pilot program is being implemented in about 50 New York City public schools and utilizes Fluidigm Technology to offer RT-PCR COVID-19 testing. New York City public schools have instituted mandatory random weekly testing in all reopened school buildings to ensure safer in-person learning.
RELATED NEWS
Follow RTT